FDA�s Commitment to Women�s Heart Health Research
Knowing
that heart disease is the leading cause of death for women, FDA�s Office of
Women�s Health has been committed to supporting cardiovascular research from
the very beginning of our research program in 1995. We�ve accomplished that by
working across several FDA Centers to support studies on issues ranging from
sex differences in cardiac interventions to the cardiotoxicity of breast cancer
drugs.
On the
heels of Heart Health Month, a new blog from OWH Director Marsha Henderson
highlights the history of FDA research on QT prolongation and demonstrates the
ways ongoing collaborations across FDA research programs are helping to advance
policies and projects to protect women�s heart health.
Read the Blog Post
|
